What's Going On With Recursion Pharmaceuticals Stock Tuesday? - Recursion Pharmaceuticals (NASDAQ:RXRX)
Recursion reported fourth-quarter revenue of $10.89 million, which missed the consensus estimate of $20.35 million. The clinical stage biotech company reported a quarterly loss of 42 cents per share, which beat estimates for a loss of 44 cents per share.
Chris Gibson Recursion Pharmaceuticals Inc Arm Holdings Recursion Pharmaceuticals Revenue Beat Reset And
Source: benzinga.com